M. Carbó López, G. Royal, C. Philouze, P. Y. Chavant, V. Blandin
FULL PAPER
CDCl3): δ = 160.9 (CO), 150.2 (CHar-o), 145.7 (Cipso), 136.4 (rac)-(2S*,5R*)-1-Hydroxy-2-isopropyl-2,3,5-trimethyl-5-(pydridin-
(CHar-p), 130.2 (C=N), 124.60 (CHar), 124.57 (CHar), 88.0 [C- 2-yl)imidazolidin-4-one (4ab): The title compound was prepared ac-
(CH ) ], 25.6 (CH N), 24.3 [(CH ) C] ppm. IR: ν = 3110, 3060, cording to Method C from 3ab (2.29 g, 9.3 mmol) and methylmag-
˜
3 2
3
3 2
2993, 2933, 2790, 1698, 1574, 1548, 1428, 1385, 1358 cm–1. HRMS
nesium chloride (2.6 m, 5.3 mL, 13.9 mmol) as a brown solid
(ESI): calcd. for C11H14N3O2 [M + H]+ 220.1081; found 220.1085.
(1.79 g, 73%), m.p. 158–160 °C. H NMR (400 MHz, CDCl3): δ =
1
8.54 (d, J = 4.3 Hz, 1 H, CHar-N), 7.70 (d, J = 8.0 Hz, 1 H, CHar-
o), 7.66–7.59 (m, 1 H, CHar-m), 7.19–7.09 (m, 1 H, CHar-p), 5.32 (s,
1 H, OH), 2.85 (s, 3 H, CH3N), 1.98–1.84 (m, 1 H, CH iPr), 1.77
(s, 3 H, CH3-C-Ar), 1.57 (s, 3 H, CH3-C-iPr), 1.07 (d, J = 6.9 Hz,
3 H, CH3 iPr), 0.77 (d, J = 6.6 Hz, 3 H, CH3 iPr) ppm. 13C NMR
(101 MHz, CDCl3): δ = 171.6 (CO), 162.0 (Cipso), 149.0 (CHar-N),
136.4 (CHar-m), 122.2 (CHar-o), 120.7 (CHar-p), 83.9 [C(Me)-iPr],
70.6 [C(Me)-Ar], 36.0 (CH iPr), 25.7 (CH3N), 19.7 (CH3-C-Ar),
4-Methyl-3-oxo-2-(p-tolyl)-1,4-diazaspiro[4.5]dec-1-ene
(3ca): The title compound was prepared according to Method A
from 1c (1.00 g, 5.5 mmol) and 4-bromotoluene (2a; 0.85 g,
1-Oxide
1
5 mmol) as a beige solid (1.20 g, 88%), m.p. 140–141 °C. H NMR
(400 MHz, CDCl3): δ = 8.69 (d, J = 8.4 Hz, 2 H, CHar-o), 7.27 (d,
J = 8.4 Hz, 2 H, CHar-m), 3.17 (s, 3 H, CH3N), 2.39 (s, 3 H, CH3-
Ar), 2.33–2.20 (m, 2 H, CH cy), 2.19–2.07 (m, 2 H, CH cy), 1.94–
1.83 (m, 2 H, CH cy), 1.83–1.66 (m, 3 H, CH cy), 1.59–1.46 (m, 1
H, CH cy) ppm. 13C NMR (101 MHz, CDCl3): δ = 162.6 (CO),
141.2 (Cipso-Me), 129.7 (C=N), 129.0 (CHar-o), 127.6 (CHar-m),
123.6 (Cipso), 86.8 (Cspiro), 34.0 (CH2 cy), 26.6 (CH3N), 23.9 (CH2
18.1 (CH3-C-iPr), 17.7 (CH3 iPr), 16.8 (CH3 iPr) ppm. IR: ν =
˜
3271, 2986, 2936, 2885, 1675, 1470, 1425, 1372 cm–1. LRMS
(ESI+): m/z = 564.1 [M + H]+. C14H21N3O2 (263.34): calcd. C
63.84, H 8.05, N 15.96; found C 63.82, H 8.03, N 15.81. On storage,
spontaneous recrystallization by sublimation provided white crys-
tals suitable for X-ray analysis.[19]
cy), 21.84 (CH -Ar), 21.76 (CH cy) ppm. IR: ν = 3034, 2947, 2925,
˜
3
2
2865, 1685, 1559 cm–1. LRMS (DCI): m/z = 273.3 [M + H]+.
C16H20N2O2 (272.35): calcd. C 70.55, H 7.42, N 10.29; found C
70.80, H 7.58, N 10.44.
1-Hydroxy-2,2,3,5-tetramethyl-5-(p-tolyl)imidazolidin-4-one (4ba):
The title compound was prepared according to Method D from 3ba
(117 mg, 0.5 mmol) and methylmagnesium iodide (1.0 m, 1.00 mL,
1.0 mmol) as a yellow solid (50 mg, 40%), m.p. 146–149 °C. 1H
NMR (300 MHz, CDCl3): δ = 7.42 (d, J = 8.1 Hz, 2 H, CHar-o),
7.14 (d, J = 8.1 Hz, 2 H, CHar-m), 5.22 (br. s, 1 H, OH), 2.87 (s, 3
H, CH3N), 2.32 (s, 3 H, CH3-Ar), 1.71 (s, 3 H, CH3-C-Ar), 1.49
(s, 3 H, CH3C), 1.31 (s, 3 H, CH3C) ppm. 13C NMR (75 MHz,
CDCl3): δ = 171.6 (CO), 139.3 (Cipso), 137.2 (Cipso-Me), 129.0
(CHar-m), 126.9 (CHar-o), 81.1 [C(CH3)2], 69.8 [C(Me)-Ar], 26.0
(CH3-C-CH3), 25.3 (CH3N), 22.0 (CH3-C-Ar), 21.1 (CH3-Ar), 20.6
Preparation of Hydroxylamines 4: Hydroxylamines 4 were prepared
by methylation of arylnitrones 3 using Method C or D.
Method C Ϫ Nitrone Methylation with MeMgCl in THF: MeMgCl
(1.5–2.0 equiv.) in THF was rapidly added to a stirred solution of
nitrone 3 in anhydrous THF (0.5–1.0 m) at room temperature
(water bath) under N2. The mixture was stirred for 15 min and
quenched by the addition of a saturated ammonium chloride solu-
tion. The aqueous layer was extracted three times with ethyl acet-
ate. The combined organic layers were washed with brine, dried
with MgSO4, filtered, and concentrated under reduced pressure.
The crude material was purified over silica gel to give the desired
hydroxylamine.
(CH -C-CH ) ppm. IR: ν = 3285, 2987, 2936, 2860, 1666, 1434,
˜
3
3
1402, 1379, 1362 cm–1. HRMS (ESI): calcd. for C14H21N2O2 [M +
H]+ 249.1598; found 249.1601.
Method D Ϫ Nitrone Methylation with MeMgI in Diethyl Ether:
MeMgI (2.0–3.5 equiv.) in Et2O was added dropwise to a stirred
solution of nitrone 3 in anhydrous Et2O (0.1 m) at 0 °C under N2
and immediate precipitation took place. The mixture was stirred
for 30 min at room temperature and quenched by the addition of
a saturated ammonium chloride solution. The aqueous layer was
extracted three times with ethyl acetate. The combined organic lay-
ers were washed with brine, dried with MgSO4, filtered, and con-
centrated under reduced pressure. The crude material was purified
over silica gel to give the desired hydroxylamine.
1-Hydroxy-2,2,3,5-tetramethyl-5-(pyridin-2-yl)imidazolidin-4-one
(4bb): The title compound was prepared according to Method C
from 3bb (811 mg, 3.7 mmol) and methylmagnesium chloride
(2.5 m, 2.2 mL, 5.6 mmol) as an orange oil (777 mg, 89%) that crys-
tallized upon standing, m.p. 116–117 °C. 1H NMR (400 MHz,
CDCl3): δ = 8.60 (br. s, 1 H, OH), 8.45 (d, J = 4.6 Hz, 1 H, CHar-
N), 7.77–7.58 (m, 2 H, CHar), 7.23–7.07 (m, 1 H, CHar-p), 2.86 (s,
3 H, CH3N), 1.77 (s, 3 H, CH3-C-Ar), 1.48 (s, 3 H, CH3C), 1.27
(s, 3 H, CH3C) ppm. 13C NMR (101 MHz, CDCl3): δ = 170.1
(CO), 162.4 (Cipso), 147.3 (CHar), 136.9 (CHar), 122.2 (CHar), 121.8
(CHar), 80.1 [C(CH3)2], 67.9 [C(Me)-Ar], 25.0 (CH3N), 23.7 (CH3-
(rac)-(2S*,5R*)-1-Hydroxy-2-isopropyl-2,3,5-trimethyl-5-(p-tolyl)-
imidazolidin-4-one (4aa): The title compound was prepared accord-
ing to Method C from 3aa (2.42 g, 9.3 mmol) and methylmagne-
sium chloride (2.6 m, 7.2 mL, 18.6 mmol) as a pale-yellow solid
(2.28 g, 89% yield), m.p. 160–161 °C. 1H NMR (400 MHz, CDCl3):
δ = 7.51 (d, J = 8.3 Hz, 2 H, CHar-o), 7.16 (d, J = 8.3 Hz, 2 H,
CHar-m), 4.36 (s, 1 H, OH), 2.81 (s, 3 H, CH3N), 2.33 (s, 3 H, CH3-
Ar), 2.00–1.83 (m, 1 H, CH iPr), 1.71 (s, 3 H, CH3-C-Ar), 1.56 (s,
3 H, CH3-C-iPr), 1.10 (d, J = 6.9 Hz, 3 H, CH3 iPr), 0.84 (d, J =
6.6 Hz, 3 H, CH3 iPr) ppm. 13C NMR (101 MHz, CDCl3): δ =
171.9 (CO), 139.9 (Cipso), 136.4 (Cipso-Me), 128.5 (CHar-m), 126.2
(CHar-o), 83.7 [C(Me)-iPr], 68.8 [C(Me)-Ar], 36.9 (CH iPr), 25.4
(CH3N), 20.7 (CH3-Ar), 19.9 (CH3-C-Ar), 17.9 (CH3-C-iPr), 17.6
C-Ar), 23.2 (CH -C-CH ), 22.7 (CH -C-CH ) ppm. IR: ν = 3153,
˜
3
3
3
3
3003, 2865, 1682, 1594, 1425, 1400, 1366 cm–1. LRMS (ESI+): m/z
= 236.2 [M + H]+, 258.1 [M + Na]+. C12H17N3O2 (235.29): calcd.
C 61.24, H 7.30, N 17.86; found C 60.76, H 7.38, N 17.79.
4-Hydroxy-1,3-dimethyl-3-(p-tolyl)-1,4-diazaspiro[4.5]decan-2-one
(4ca): The title compound was prepared according to Method D
from 3ca (136 mg, 0.5 mmol) and methylmagnesium iodide (1.7 m,
1.03 mL, 1.75 mmol) as a yellow solid (80 mg, 55%), m.p. 180–
182 °C. 1H NMR (400 MHz, CDCl3): δ = 7.50 (d, J = 8.1 Hz, 2
H, CHar-o), 7.08 (d, J = 8.1 Hz, 2 H, CHar-m), 5.03 (s, 1 H, OH),
2.82 (s, 3 H, CH3N), 2.44–2.24 (m, 1 H, CH cy), 2.30 (s, 3 H, CH3-
Ar), 1.84–1.46 (m, 6 H, CH cy), 1.62 (s, 3 H, CH3-C-Ar), 1.41–
1.06 (m, 2 H, CH cy), 0.98–0.88 (m, 1 H, CH cy) ppm. 13C NMR
(101 MHz, CDCl3): δ = 173.6 (CO), 141.9 (Cipso), 136.7 (Cipso-Me),
129.0 (CHar-o), 125.6 (CHar-m), 84.5 (Cspiro), 73.1 [C(Me)-Ar], 33.5
(CH2 cy), 31.7 (CH2 cy), 25.8 (CH3N), 25.08 (CH2 cy), 25.04 (CH3-
(CH3 iPr), 16.7 (CH3 iPr) ppm. IR: ν = 3319, 2971, 2938, 1666,
˜
1429, 1368 cm–1. HRMS (ESI): calcd. for C16H25N2O2 [M + H]+
277.1911; found 277.1914.
Compound (2S,5R)-4aa was prepared according to Methods A and
D from (S)-1a (1.4 g, 9.9 mmol) and 4-bromotoluene (2a; 1.88 g,
11 mmol) as a yellow-white solid (1.95 g, 76%), m.p. 168–169 °C.
[α]2D0 = –111.7 (c = 0.46, CHCl3).
C-Ar), 23.2 (CH cy), 22.7 (CH cy), 21.1 (CH -Ar) ppm. IR: ν =
˜
2
2
3
4892
www.eurjoc.org
© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 2014, 4884–4896